Group items tagged

Medical professionals often prescribe semaglutide to patients who have type 2 diabetes. Along with a balanced diet and regular exercise, it has also shown to be an incredibly efficient weight loss aid for patients. As the active ingredient in well-known brand-name drugs such as Wegovy, Ozempic, and Rybelsus, semaglutide is currently on everybody's lips. But what exactly is semaglutide? Does it really work for weight loss? We'll find an answer for you in this article, and explain the main benefits of using semaglutide for weight loss. What Is Semaglutide? A number of diabetic and weight loss medications, including Wegovy, Ozempic, and Rybelsus, have semaglutide as their active ingredient. This substance is a synthetic form of the hormone glucagon-like peptide-1 (GLP-1), that occurs naturally. Developed by the company Novo Nordisk, semaglutide was first approved by the FDA in 2017 as an injection for the treatment of adult type 2 diabetes (as part of the approval procedure for Ozempic). In 2019, the Food and Drug Administration approved a novel semaglutide form known as Rybelsus. Rybelsus was the first oral GLP-1 receptor agonist for the treatment of type 2 diabetes in the United States.

The Pharmacist's Defence Association (PDA) has raised concerns over the adoption of Digital Clinical Excellence (DiCE) guidelines for online prescribing of GLP-1 receptor agonists for weight management in adults. This follows a clash with expert recommendations commissioned by the General Pharmaceutical Council (GPhC) as the PDA "believes the final guidance conflicts with the expert opinion underpins the GPhC's prosecution strategy towards pharmacist prescribers under investigation." In a recent statement, the PDA highlighted the discrepancy between DiCE's guidance and the expert report employed by the GPhC to prosecute pharmacist prescribers using a questionnaire-based consultation model. This conflict has prompted the PDA to withhold its endorsement of the DiCE guidance as it differs from an expert report commissioned by the GPhC. The PDA's reservations stem from the inherent risks associated with questionnaire-based prescribing.

Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder characterized by differences in brain function and activity impacting attention, executive functioning, and impulse control. It often manifests in childhood and can persist into adulthood. While commonly associated with hyperactivity and fidgeting, ADHD presents on a spectrum with diverse symptoms and varying intensities.The exact cause of What Is ADHD is not fully understood, but it's likely due to a complex interplay of genetic and environmental factors. Genetics play a significant role, with ADHD often running in families. However, environmental factors like prenatal exposure to certain substances, childhood trauma, and brain injuries can also contribute. Core Symptoms: The core symptoms of ADHD fall into three main categories: Inattention: Difficulty focusing, sustaining attention, making careless mistakes, easily distracted, forgetting tasks. Hyperactivity: Fidgeting, squirming, excessive movement, difficulty remaining seated, feeling restless. Impulsivity: Acting without thinking, blurting out answers, interrupting others, difficulty waiting turns. It's important to remember that not everyone with ADHD experiences all symptoms to the same degree. Some individuals might primarily struggle with inattention, while others exhibit more hyperactive or impulsive tendencies. Additionally, the presentation can change over time and across different situations.

Pharmacy2U has joined thousands of pharmacists in launching the new NHS Pharmacy First service in England. The new service, which was first launched on 31 January 2024, enables pharmacists to treat seven common health conditions without the need for a GP appointment or prescription. Over 95 per cent of all community pharmacies in the country (10,265 in total) have signed up to provide the service, which is aimed at easing pressure on GP services while giving patients quick and accessible care. Under the Pharmacy First service, the online pharmacy is offering same-day appointments to manage six conditions: sinusitis, an infected insect bite, sore throat, UTIs, shingles and impetigo. Pharmacy2U's CEO Kevin Heath said that they support the initiative fully and that the service will play a major role in providing patients easy and direct access to pharmacists.

Recent NHS data sheds light on the evolving landscape of fit note certification, indicating a gradual expansion of roles beyond traditional medical practitioners to pharmacists and nurses. This uptake in numbers coincides with the Department of Work and Pensions's (DWP) call for evidence in relation to fit note reform which will remain open till 8 July 2024. According to figures published by NHS Digital, during the nine-month period from April 2023 to December 2023, pharmacists certified a significant number of fit notes. Approximately 1.4 per cent of fit notes of the 8 million were issued by pharmacists while the rest were issued by the GP surgeries reflecting the impact following legislative amendments in July 2022, which extended certification authority to pharmacists, nurses, occupational therapists, and physiotherapists. In June 2022, the Pharmacists' Defence Association (PDA) advised pharmacists not to sign fit notes where the required therapeutic, diagnostic, or examination skills lie outside their scope of competence. The association remarked that healthcare professionals needed mandatory training under the Health Education England before they are fit to issue fitness notes to the public.

A recent report from Healthwatch England has highlighted that while people highly value the accessibility of community pharmacies, both in terms of location and prompt service, they also encounter challenges in getting the most out of their pharmacy care experience. The report titled 'Pharmacy: What People' is based on the research conducted by the organisation in November last year, involving 1,650 people who shared their experiences of pharmacy services in England. It showed the country's notable dependence on community pharmacies, with 72 per cent of respondents saying they have used a community pharmacy in the past three months. Usage of online pharmacies is considerably lower than community pharmacies, with only 18 per cent of individuals having used an online pharmacy in the past three months, according to the report published on Tuesday (30 April).

Thanks to a new service added to the NHS App, patients in England can now see their prescriptions online and collect their prescribed medication from the nominated pharmacy or a pharmacy of their choice without a paper prescription. NHS England has introduced digital prescriptions in the app following a successful trial last year involving over a million users. Users without a nominated pharmacy can collect their prescriptions from any pharmacy using the barcode in the app, but this is not required for patients with a nominated pharmacy as details would be sent to their pharmacy electronically. From now on, patients waiting for elective hospital treatment can also check the average waiting time for their procedure at their local trust using the NHS App.

A new study has underscored the significance of offering customers a variety of payment choices, particularly as digital platforms gain popularity among younger age groups. Almost one in three (30 per cent) people surveyed by payments solutions provider, Access PaySuite reported a negative experience when purchasing health and wellbeing products or services due to limited payment options. The research showed that online and in-person cash payments were the most preferred modes of payment, while more than a quarter of consumers expressed their preference for paying through Direct Debit. About 17 per cent of the participants favoured using a mobile app for payments during the booking process, followed by mobile in-person options like Google Pay (14 per cent) and phone-based transactions using debit or credit card) (13 per cent).

People in the UK have a high level of trust in pharmacies and many are keen on seeing the Pharmacy First initiative expanded, according to the 2024 STADA Health Report published today (24 June). The 10th annual health report by global healthcare leader STADA Arzneimittel AG, the parent company of Thornton & Ross, involved a survey of over 46,000 respondents across 23 countries, including 2,000 participants from the UK. The UK data showed an overwhelming trust in UK pharmacies, with 94 per cent of those surveyed (more than nine out of 10 Brits) saying they have only ever had good advice from a pharmacist. The report also indicated a strong desire for the Pharmacy First scheme to be expanded, with 44 per cent of respondents advocating for an increase in pharmacists' scope of responsibilities to support doctors.

Community pharmacists in England have launched a new digital platform called My Local Surgery, enabling patients to access Pharmacy First consultations online. This initiative, a part of the NHS Pharmacy First scheme, facilitates free video consultations for six common conditions, connecting patients with community pharmacists for clinical advice and treatment. The platform, spearheaded by a team of pharmacy, tech, and clinical services experts, including experienced community pharmacists Darren Lingaloo and Gulraj Dhillon, tech specialist Nav Ramiah, and Dr. Adam Kirk, a seasoned NHS and digital healthcare professional, seeks to meet the rising demand for clinical services. Darren Lingaloo, co-founder and chief pharmacist at My Local Surgery, said: "The evolving role of pharmacists is long overdue and has the potential to save millions of GP appointments every year.